An observational study in Breast Cancer, sponsored by Institut Cancerologie de l'Ouest. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by Institut Cancerologie de l'Ouest · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Breast Neoplasms by Institut Cancerologie de l'Ouest — 7 open to participants now, 12 under way, none of them phase 3. Breast Neoplasms · Institut Cancerologie de l'Ouest.
Among the 35 studies in Breast Neoplasms by Institut Cancerologie de l'Ouest, this one is the 6th largest by enrollment of the 12 observational ones that give a count, is one of 7 that started in 2019, is one of 12 observational ones, and was the 16th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →7 of the 35 studies in Breast Neoplasms by Institut Cancerologie de l'Ouest are open now, in 1 country. Recruiting first, the newest first:
Institut Cancerologie de l'Ouest · Sites in France
Ages 18+
Institut Cancerologie de l'Ouest · Sites in France
Ages 18+ · Women only
Institut Cancerologie de l'Ouest · Sites in France
Ages 18+
Institut Cancerologie de l'Ouest · Sites in France
Ages 40+ · Women only
Institut Cancerologie de l'Ouest
Ages 18+ · Women only
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 7 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 200 is close to the median of 184 across 3,239 observational studies indexed under Breast Neoplasms.
Median enrollment 140 across the 23 interventional studies, 195 across the 12 observational. Of the 20 that completed or were terminated, 4 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
Institut Cancerologie de l'Ouest is the lead sponsor of 109 studies on the registry; 20 are open to participants now.
2 of the studies in Breast Neoplasms by Institut Cancerologie de l'Ouest that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06962163Institut Cancerologie de l'OuestAssessement of Potential Interest of [68Ga]Ga-PentixaFor PET/CT in Metastatic Triple Negative Breast Cancer Patients | 2027-06 |
| NCT06800989Institut Cancerologie de l'OuestTo Assess the Contribution of Sophrology Assisted by an Ambulatory Device on the Anxiety of Patients Undergoing Chemotherapy for the Treatment of Localized Breast Cancer | 2027-08-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 35 studies in Breast Neoplasms by Institut Cancerologie de l'Ouest, from their registry updates:
This tab as a report to print or save as PDF → With an account.
More and more patients report taking dietary supplements based on herbal medicine, aromatherapy, vitamintherapy,... in the course of their detoxifying anticancer chemotherapy, to stimulate the immune defenses, to relieve and/or decrease the side effects of chemo or even to act against cancer. At European level, there are between 15 and 73% of patients treated for cancer taking a dietary supplement (in particular phytotherapy) or a great heterogeneity according to the studies. However, there is still little evidence of the efficacy of these dietary supplements. A large proportion of patients do not seem to inform their doctor about the use of dietary supplements. Patients using dietary supplements most often ignore the mode of action of these products and generally say they are not informed.
In 2015, at the West Cancerology Institute (ICO), 5 patient files were analyzed taking this type of treatment in addition to chemotherapy; in 2016, 24 files; 2017, 61 patient records and this continues to progress.
At the same time, a product appears very frequently associated with cancer chemotherapy: Desmodium Adscendens, an African plant with in vitro properties of liver protector. The Desmodium contains triterpene saponins, alkaloids, flavonoids, polyphenols, and tryptamine derivatives.
Morevover, several situations of patients undergoing chemotherapy and taking long-term Desmodium, with hepatic cytolyses were experienced, not explained by the usual treatments (case described in the literature).
Therefore, this study will evaluate these new therapeutic modalities that are included in the intake of chemotherapy in order to better know them to improve the therapeutic taking of patients and to focus on the impact of Desmodium in association with chemotherapy.
Patients of the ICO René Gauducheau taken care at day hospital for IV chemotherapy treatment of breast cancer in neoadjuvant and/or adjuvant situation.
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
patients taking dietary supplements with Desmodium
Other: dietary supplements questionaire · Other: Liver function
patients taking dietary supplements without Desmodium
Other: dietary supplements questionaire · Other: Liver function
patients not taking any dietary supplements
Other: Liver function
Patient questionaire to be completed by the patient at the last cycle
Liver blood test to be performed from the first to the last chemotherapy cycle
Prevalence of Dietary Supplement Use During IV Chemotherapy
Number of participants using dietary supplements during IV chemotherapy, including dietary supplements containing Desmodium and dietary supplements not containing Desmodium, compared with participants not using dietary supplements (control group).
Time frame: 12 months
Incidence of Hepatic Cytolysis From the First to the Last Treatment Cycle
% of participants with hepatic cytolysis undergoing chemotherapy between the first and last treatments
Time frame: 12 months
Percentage of Participants Taking Each Type of Dietary Supplement
Dietary supplement use was extracted from patient-reported products recorded at the last chemotherapy cycle. Participants were classified into 'with Desmodium' and 'without Desmodium' groups based on the presence of Desmodium-containing products. Supplement categories (homeopathy, phytotherapy, aromatherapy, vitamin supplementation, mineral supplementation, probiotics, and gemmotherapy) were not mutually exclusive. Participants could report the use of more than one type of dietary supplement; therefore, percentages may total more than 100% within a group.
Time frame: 12 months
| Milestone | Control Group | Dietary Supplements Group Without Desmodium | Dietary Supplements Group With Desmodium |
|---|---|---|---|
| Started | 101 | 82 | 17 |
| Completed | 101 | 82 | 17 |
| Not completed | 0 | 0 | 0 |
Number of participants using dietary supplements during IV chemotherapy, including dietary supplements containing Desmodium and dietary supplements not containing Desmodium, compared with participants not using dietary supplements (control group).
| Participants | Control Group | Dietary Supplements Group Without Desmodium | Dietary Supplements Group With Desmodium |
|---|---|---|---|
| Prevalence of Dietary Supplement Use During IV Chemotherapy | 0 | 82 | 17 |
% of participants with hepatic cytolysis undergoing chemotherapy between the first and last treatments
| Percentage of participants | Control Group | Dietary Supplements Group Without Desmodium | Dietary Supplements Group With Desmodium |
|---|---|---|---|
| Incidence of Hepatic Cytolysis From the First to the Last Treatment Cycle | 30.7 | 31.7 | 56.3 |
Dietary supplement use was extracted from patient-reported products recorded at the last chemotherapy cycle. Participants were classified into 'with Desmodium' and 'without Desmodium' groups based on the presence of Desmodium-containing products. Supplement categories (homeopathy, phytotherapy, aromatherapy, vitamin supplementation, mineral supplementation, probiotics, and gemmotherapy) were not mutually exclusive. Participants could report the use of more than one type of dietary supplement; therefore, percentages may total more than 100% within a group.
| Percentage of participants | Control Group | Dietary Supplements Group Without Desmodium | Dietary Supplements Group With Desmodium |
|---|---|---|---|
| Homeopathy | 0 | 18 | 29 |
| Phytotherapy | 0 | 49 | 100 |
| Aromatherapy | 0 | 24 | 29 |
| Vitamin therapy | 0 | 22 | 18 |
| Mineral supplementation | 0 | 12 | 12 |
| Probiotics | 0 | 10 | 6 |
| Gemmotherapy | 0 | 1 | 0 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Control Group | — | — | — |
| Dietary Supplements Group Without Desmodium | — | — | — |
| Dietary Supplements Group With Desmodium | — | — | — |
| Age, Continuous(years) | Control Group | Dietary Supplements Group Without Desmodium | Dietary Supplements Group With Desmodium | Total |
|---|---|---|---|---|
| Median | 57 (44 to 67) | 49 (43 to 59) | 56 (42 to 58) | 52 (43 to 64) |
| Sex: Female, Male(Participants) | Control Group | Dietary Supplements Group Without Desmodium | Dietary Supplements Group With Desmodium | Total |
|---|---|---|---|---|
| Female | 101 | 82 | 17 | 200 |
| Male | 0 | 0 | 0 | 0 |
| Race and Ethnicity Not Collected(Participants) | Control Group | Dietary Supplements Group Without Desmodium | Dietary Supplements Group With Desmodium | Total |
|---|---|---|---|---|
| Count of participants | — | — | — | 0 |
| Region of Enrollment(participants) | Control Group | Dietary Supplements Group Without Desmodium | Dietary Supplements Group With Desmodium | Total |
|---|---|---|---|---|
| France | 101 | 82 | 17 | 200 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2019 to primary completion in May 2020, 13 months.
Results were first posted in Nov 2026, 6 years 5 months after primary completion.
Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's 13 months is below that.
Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institut Cancerologie de l'Ouest →